Merial Overview
- Founded
-
1997

- Status
-
Acquired/Merged
- Employees
-
6,900

- Latest Deal Type
-
M&A
- Financing Rounds
-
3
- Investments
-
7
Merial General Information
Description
Manufacturer of animal medicines. The company deals with animal health, vaccines, veterinary medicines and other pharmaceuticals.
Contact Information
Website
www.merial.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Distributors/Wholesale
Other Industries
Pharmaceuticals
Acquirer
Boehringer Ingelheim
Primary Office
- 29, Avenue Tony Garnier
- 69007 Lyon
- France
Merial Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Merial Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Manufacturer of animal medicines. The company deals with animal health, vaccines, veterinary medicines and other pharmac
Distributors/Wholesale
Lyon, France
6,900
As of 2017
000000&0
Merial Competitors (1)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
0000 00000 0000000 | Private Equity-Backed | Libourne, France | 0000 | 00000 | 000000000 | 00000 |
Merial Patents
Merial Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20140271708-A1 | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g | Abandoned | 15-Mar-2013 | 0000000000 | |
US-20130177591-A1 | Lipid based adjuvants for dna plasmids | Abandoned | 10-Jan-2012 | 000000000 | |
US-20130079394-A1 | Indirect modeling of new repellent molecules active against insects, acarids, and other arthropods | Abandoned | 23-Sep-2011 | 0000000000 | 0 |
CA-2784141-A1 | Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles | Granted | 17-Dec-2009 | 0000000000 | |
CA-2784141-C | Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles | Active | 17-Dec-2009 | C07D471/04 |
Merial Signals
Merial Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Merial Investments & Acquisitions (7)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000 0000000 | 02-Mar-2015 | 000000000 | Buildings and Property | 0000000 0 | |
00000 (000000 | 12-Feb-2015 | 0000000000 | Pharmaceuticals | 0000000 0 | |
00000 0000000 | 31-Jan-2013 | 0000000000 | Other Pharmaceuticals and Biotechnology | 000é 0000 | |
0000000 00000 | 02-Apr-2012 | 0000000000 | Pharmaceuticals | ||
Scynexis | 27-Mar-2008 | Later Stage VC | 000.00 | Drug Discovery |
Merial Exits (2)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
0000000 0000000000 | 02-Apr-2012 | 000000000000000000 | Completed |
|
|
Scynexis | 27-Mar-2008 | Later Stage VC | 000.00 | Completed |
|